Featured Clinical Trial:

Hepatocellular carcinoma (product/compound: Sorafenib)

ClinicAid Locations: Southern California – Fountain Valley

Status: Enrollment closed.

Condition: Hepatocellular Carcinoma

Product Name/Compound: Sorafenib

Full Study Title: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (GIDEON)

Study Summary: Non-interventional study of safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC). (Observational Study)

Eligible Participants:

Inclusion (Eligible):

• Outpatients with histologically/cytologically documented or radiographically diagnosed unresectable HCC who are candidates for systemic therapy and for whom a decision to treat with Nexavar has been made. Radiographic diagnosis HCC NIS, needs typical findings of HCC by radiographic method i.e. on multi-dimensional, dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP), or MRI.
• Patients must have a life expectancy of at least 8 weeks

Exclusion (Not Eligible):

• Exclusion criteria must follow the approved local product information

Study Phase: Phase IV (What are Phases?)

To receive information and updates for this trial:
Please contact us and mention the Trial ID below.

Trial ID (ClinicalTrials.gov): NCT00812175

<< Back to all ClinicAid clinical trials